Kornimate/medical-research-clean huggingface dataset:
photobiomodulation therapy treatment on facial paralysis

Conditions: Facial Paralysis

Summary: objective: facial paralysis can be caused by a variety of etiological factors, complete palsy continues for two months, the chance of full recovery is reduced to zero. the aim of this study was to evaluate the effectiveness of photobiomodulation therapy (pbmt) in the in patients undergoing facial paralysis over 8 weeks. methods: this study was an open-label, not concurrent control study including 54 patients that underwent facial paralysis over 8 weeks. patients were assigned to the pbmt group and control group, with 27 patients in each group. laser treatments were applied 3 days a week after recruited. pbmt was delivered using a class iv multi-wave locked system that combines with a simultaneous 808 nm continuous emission and 905 nm pulse emission and the maximum peak power was 25 w. clinical outcome measure comprised the house-brackmann grading system, facial clinimetric evaluation scale (face), sunnybrook facial grading scale (sbfg), and electrophysiological testing, including electroneuronography (enog), electromyography (emg) and blink reflex. all the measurements were collected at the first day and at the end of study. all reported p values were two-sided and were declared statistically significant when less than 0.05.


Eligibility criteria:
inclusion criteria: - (1) adults over 18 years of age and under 65 years of age. (2) had not received medicine, such as prednisolone. (3) had history of bell's palsy, ramsay hunt syndrome, traumatic facial paralysis and history of otological surgery. (4) disease duration longer than two months. exclusion criteria: - (1) complete facial paralysis (hb 6). (2) greater than 90% denervation on enog. (3) no voluntary emg activity. (4) no latency of early (r1) and late (r2, r2') components in blink reflex. (5) serious mental illness or social problems, and neurological disorders. (6) systemic disease, such as severe diabetes, malignant tumors and other serious consumptive diseases. (7) planning for pregnancy, in pregnancy or lactation.

Keywords: facial paralysis photobiomodulation enog emg hb grading
national register of moderate and severe adult atopic dermatitis

Conditions: Atopic Dermatitis

Summary: collect clinical history and treatment data of ad in adulthood;

atopic dermatitis is a chronic-recurrent inflammatory skin disease with high prevalence in children and frequently presenting clinical remission during or after childhood; however, it may persist and/or recur, even after long and transient remission, adulthood. in addition, in some adult patients, da is not present in pediatric age, but onset in adulthood: the investigators speak, in these cases, of adult-onset da. the prevalence of da is increasing all over the world and the cases in which clinical manifestations appear or persist during adolescence and/or adulthood are increased especially in industrialized countries. are not currently available specific laboratory markers for diagnosis of da and, therefore, diagnosis is eminently clinical. in fact, at the present time, there are no validated diagnostic criteria, nor is there a clear consensus on diagnostic-therapeutic pathway to be followed when evaluating patients with adult da. for these reasons, the collection of data related to various aspects of the da such as those epidemiological, medical and clinical history, as well as the impact of the disease on the quality of life, results of crucial importance for estimating the real prevalence of this disease in italy and also, possibly, to outline possible diagnostic criteria specific to adult da, so that to facilitate and improve the diagnostic-therapeutic path of the patient. the intention of the project, therefore, is to create and use a national register dedicated to da patients in adulthood regardless of the period of onset of their pathology. aim to place the italian register as a supranational reference for international studies conducted on the adult da.

Eligibility criteria:
inclusion criteria: 1. age 18 years 2. signature of informed consent 3. diagnosis of moderate and/or severe da by a dermatologist specialist defined on the basis of following criteria (10): * easi 16 * easi \<16 but with at least one of the following conditions: 1. location in at least one of the following "critical" locations: face, hands, genitals 2. qid \> 10 3. vas itching \> 7 4. vas sleep \> 7 exclusion criteria: 1. patient unable to provide informed consent prior to any collection procedures data on the study; 2. unable to complete the procedures required for the study; 3. a patient already participating in another follow-up register of the same disease.
comparison of meal replacements versus protein supplements and utilizing the protein digestibility corrected amino acid score (pdcaas) method

Conditions: Protein Deficiency

Summary: the purpose of this research study is to compare the varying qualities of protein supplements utilizing the protein digestibility corrected amino acid score (pdcaas) method and evaluating the clinical outcome related to protein stores and absorption.

the pdcaas has been adopted by the food and agricultural organization (fao) of the world health organization (who) and is currently recognized as the standard method to evaluate protein quality. this study will also examine patient tolerability, satiety, and satisfaction while using meal replacements versus protein supplements. this research study looks to gain knowledge on the varying qualities of protein and find the most effective protein supplement and/or meal replacement that provides increased patient compliance and promotes a healthy recovery.

Eligibility criteria:
inclusion criteria: * persons that are scheduled to undergo the adjustable gastric banding (agb) surgery utilizing the ap lap-band system. * not having any medical confounding factors as described in exclusion criteria. * willing to comply with food and exercise logs and comply with the full-liquid diet, both pre-and-post-operatively. exclusion criteria: * persons who are not undergoing agb surgery or are unwilling to comply with study methods or are medically not eligible. * taking diuretics * have been diagnosed with unstable diabetes, unstable neurologic conditions, unstable cardiac conditions or gastro-intestinal disorders, renal dysfunction, wounds, and autoimmune disorders that may increase protein needs. * uncontrolled gastrointestinal disease, such as crohn's disease, diverticulitis, celiac disease, or ulcerative colitis. * active malignancy * patients will also be excluded if pre-operative vitamin deficiencies are not corrected by surgery.

Keywords: pdcaas bariatric patient
bridging gaps in the neuroimaging puzzle: new ways to image brain anatomy and function in health and disease using electroencephalography and 7 tesla magnetic resonance imaging

Conditions: Healthy; Epilepsy; Psychosis; Essential Tremor

Summary: the human brain presents outstanding challenges to science and medicine. brain function and structure span broad spatial scales (from single neurons to brain-wide networks) as well as temporal scales (from milliseconds to years). currently, none of the tools available for studying the brain can fully capture its structure and function across these diverse scales - "the neuroimaging puzzle". this poses crucial limitations to understanding how the brain works, and how it is affected by numerous diseases. the central goal of this project is to expand currently available tools for non-invasive human brain imaging, to bridge critical gaps in the neuroimaging puzzle. new methodologies will be developed, focused on ultra-high field magnetic resonance imaging (uhf mri) and its combination with electroencephalography (eeg). new contrast mechanisms and technological advances enabled by uhf mri and eeg will be explored to allow unprecedented views into the microstructure of brain regions like the thalamus, and to capture the activity of large-scale neuronal networks in the brain with high sensitivity, temporal and spatial specificity. these advances will be directly applied to address open questions in the diagnosis and treatment of essential tremor, and psychosis. in general, improved brain imaging techniques are critical for a deeper understanding of how the brain works, and to detect and characterize diseases more effectively, thereby improving clinical management and leading to a healthier population. the non-invasive characterization and treatment of neurodegenerative diseases like tremor is particularly relevant to aging modern societies.


Eligibility criteria:
inclusion criteria: * common to all participant groups: be 18 years old or older; be able to understand instructions; be able to provide informed consent. * specific to healthy participants: have no history of neurological or mental disorders; normal vision or corrected-to-normal using contact lenses. * specific to the patient groups: not be hospitalized; having been diagnosed with tremor, epilepsy or psychosis and invited to participate by our team's clinicians; for some groups: normal vision or corrected-to-normal using contact lenses. exclusion criteria: * contra-indications for mri (e.g. an implant that is not mri-compatible), also including having claustrophobia or being pregnant. * inability to follow the necessary tasks of the study (e.g. unable to lie on the scanner bed). * having undergone brain surgeries in the past.

Keywords: electroencephalography magnetic resonance imaging ultra-high field neuroimaging
impact of coronary anatomy on angina relief in patients undergoing coronary revascularization

Conditions: Angina; Status Post PCI; Status Post CABG

Summary: we hypothesize that coronary artery disease (cad) severity assessed by syntax score is an independent predictor of recurrent or persistent angina following coronary revascularization. the syntax score is a score that suggests the severity of coronary artery disease detected by coronary angiography. coronary revascularization is a procedure that occurs in two ways, a percutaneous coronary intervention (pci) and a coronary artery bypass graft (cabg) and is done when there is narrowing and blockage or hardening of the arteries (atherosclerosis) surrounding the heart. narrowing and blockages reduce blood flow to parts of the heart causing chest pain (known as angina) and sometimes myocardial infarction.

pci and cabg are two well-established revascularization approaches to treatment of chronic angina caused by coronary atherosclerosis. nevertheless, 35-42% of patients report recurring or persisting anginal symptoms after coronary revascularization. this can be attributed to many structural and functional causes, prominent amongst which is pre-revascularization angina severity, unrevascularized coronary territory, progression of native or bypass graft atherosclerosis, restenosis (re-narrowing of the vessels) and accompanying adjunctive pharmacotherapy. the syntax score is an angiographic tool for grading the complexity of coronary disease. it is the sum of points assigned to coronary lesions within one of the 16 segments of the coronary tree. the segments are given a 1,2, or 5 based on the disease presence as defined by the american heart association classification. the syntax score has been used to help predict the outcomes of patients undergoing pci with 3-vessel involvement (e.g. a triple bypass or 3-stent placement pci). those patients with the highest scores had the highest risk of a poor outcome with pci revascularization compared to cabg. despite these observations, the impact of cad severity on post-revascularization angina, using the syntax has never been systematically addressed in the current era.

Eligibility criteria:
inclusion criteria: * any va patient who has had an pci from january 1, 2003 and december 31, 2011 and in the database used in protocol 09-018 (va-cap study). * any va patient who has received or will receive a 1-year follow up. exclusion criteria:

Keywords: angina syntax coronary pci cabg
optimization of management in patients with cardiovascular disease after lower limb joint replacement

Conditions: Thromboembolism; Anticoagulant-induced Bleeding

Summary: the goal of the study is to evaluate the frequency of cardiovascular and thromboembolic complications in patients with cardiovascular disease after lower limb joint replacement, the influence of known risk factors and strategies for perioperative prevention of thromboembolic complications on the frequency of cardiovascular complications and to develop approaches to optimize antithrombotic prevention tactics.


Eligibility criteria:
inclusion criteria: * informed consent * age older than 18 y.o. * cardiovascular disease * indications for planned lower limb joint replacement surgery exclusion criteria: * pregnancy * psychiatric disorders * decompensated heart failure or acute heart failure * known diagnosis of cancer

Keywords: joint replacement prognosis anticoagulation regimen thromboembolism venous thromboembolism
stereotactic body radiation therapy for spinal metastases in favorite tumors

Conditions: Breast Cancer; Prostate Cancer; Non Small Cell Lung Cancer

Summary: stereotactic body radiation therapy(sbrt) for spinal metastases has been proved a good results in pain relieve and local control, however,the longterm of efficacy and safety of this regimen is unclear.the purpose of the study is to evaluate the longterm outcome of this therapeutic regimen in selective patients who will be survival more than 2 years.

recently,stereotactic body radiation therapy(sbrt) become an alternative regimen for spinal metastases due to it's high dose cover the metastatic lesion and low dose in the adjacent spinal cord which result in more efficacy and less toxicity. however,the longterm of efficacy and safety of this regimen is unclear because of shortly median survival among unselective spinal metastases.to our knowledge,the median survival of some favorite metastatic diseases will be more than two years if they received appropriate system therapy.these include hormones dependent brest cancer/prostate cancer,and egfr mutation non-small cell lung cancer(nsclc) ect.the purpose of the study is to evaluate the longterm outcome of this therapeutic regimen in selective patients who will be survival more than 2 years.

Eligibility criteria:
inclusion criteria: 1. who scores 0-2; 2. the primary lesion was confirmed by pathology or cytology; 3. the metastatic lesions were diagnosed by imaging(ct,mri,pet-ct,ect),or the lesions were confirmed by biopsy; 4. the metastatic lesion was limited in 3 consecutive vertebral bodies; 5. the baseline pain score was ≥5(nrps) and the use of analgesic drugs was recorded; 6. the enhanced mri scan of involved vertebral bodies was required in the 2 weeks before radiotherapy; adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: 1. leukocytes ≥ 3.0 x109/ l; 2. absolute neutrophil count (anc) ≥ 1.5 x109/ l; 3. platelet count ≥ 100 x109/ l; 4. hemoglobin (hb) ≥ 9g/ dl; 5. total bilirubin ≤1.5 x the upper limit of normal (uln); 6. alanine aminotransferase (alt) ≤ 3 x uln; 7. aspartate aminotransferase (ast) ≤ 3 x uln; 8. serum creatinine ≤ 1.5 x the uln; 9. signed informed consent; exclusion criteria: 1. there were significant changes in the shape of the vertebral body (the height of the vertebral body was compressed≥ 50%) or the vertebral body was unchanged but the volume of the dissolving bone was≥ 50% and could lead to serious bone adverse events; 2. there were \>3 consecutive vertebral bodies involved; 3. spinal cord compression has occurred; 4. the gap between tumor and spinal cord was less than 3mm; 5. the metastatic area previously received radiation; 6. pregnant and nursing women; 7. uncontrolled co-morbid illnesses; 9.refused to signed informed consent;

Keywords: spinal metastases stereotactic body radiation therapy(sbrt) breast cancer prostate cancer non small cell lung cancer
onabotulinumtoxina intradetrusorial injections and ngf expression

Conditions: Overactive Detrusor; Detrusor Hyperreflexia of Bladder

Summary: in the last years, botulinum toxin type a (onab/a) has been increasingly used as a treatment option for overactive bladder symptoms in patients affected by either neurogenic and idiopathic detrusor overactivity (do). how onab/a injected into the detrusor muscle improves overactive bladder symptoms in neurologic patients has been only partially investigated.some evidence suggested that the neurotoxin probably reduces detrusor muscle contraction blocking detrusor muscle cholinergic innervation. however, recent experimental observations indicated that onab/a determines more complex effects on bladder activity acting on afferent innervations as well as on the efferent one. only few experimental studies have investigated the activity of onab/a on bladder afferent nervous transmission. experimental studies in animals showed that nerve growth factor (ngf) elicits increased sensation, urgency and do. although there are some evidence on the ability of onab/a to improve do and to reduce bladder and urinary content of ngf, how onab/a influences ngf expression and the expression of trka, p75 and trpv1 receptors is still unclear. the hypothesis is that onab/a reduces ngf bladder tissue levels and in the same time it modulates the gene expression of ngf associated receptors (trka, p75 and trpv1).

ngf has been suggested to modulate neurotransmitters' release, induces synaptic reorganization and influences neuronal excitability acting on trk/a and p75 associated receptors. moreover, recent observations indicated that ngf-induced do and noxious input depend on the interaction of ngf with trpv1, that is over-expressed in overactive bladders and interstitial cystitis/painful bladder syndrome. from a clinical point of view, a decrease in urinary ngf levels has been detected in patients with do treated with onab/a. although there are some evidence on the ability of onab/a to improve do and to reduce bladder and urinary content of ngf, how onab/a influences ngf expression and the expression of trka, p75 and trpv1 receptors is still unclear.

Eligibility criteria:
inclusion criteria: patients affected by refractory overactive bladder (oab) symptoms and detrusor overactivity (idiopathic and neurogenic do) refractory to conventional anticholinergics (at least 3 antimuscarinic agents -- tolterodine, oxybutynin and solifenacin -- each taken for at least 1 month). exclusion criteria: * oab symptoms due to bladder outlet obstruction because of urogenital prolapse in females and benign prostatic hyperplasia in males, * recurrent urinary tract infections, * cognitive impairment, * pregnancy, * anticoagulant therapy, * psychoactive agents modulating bladder function (venlafaxine, amitriptyline), aminoglycosides, and other drugs thought to interfere with bladder function

Keywords: idiopathic detrusor overactivity neurogenic dysfunction onabotulinumtoxina
darbepoetin alfa in patients with "poor prognosis" germ cell tumor treated with high-dose chemotherapy (hd-vip)

Conditions: Dysgerminoma

Summary: the aim is to determine the frequency of rbc transfusion in patients with metastatic "poor prognosis" germ cell tumor during high-dose chemotherapy (hd-vip, level 6) with or without darbepoetin alfa


Eligibility criteria:
inclusion criteria: * poor prognosis" according igcccg-criteria: * primary mediastinal tumor * gonadal/retroperitoneal germ cell tumor with visceral metastases except of lung * poor marker: afp \> 10.000 ng/ml or beta-hcg \> 10.000 ng/ml (50.000 iu/l) andd ldh \>10 x upper normal limit * no previous chemotherapy * age \> 18 years * performance-status: who =\< 2 * written informed consent * ability to give informed consent exclusion criteria: * hemolysis * hematological disease with insufficient erythropoiesis * patients without sufficient treatment of sideropenia, folate deficiency or vitamin b12 deficiency * uncontrolled arterial hypertension * treatment with rh-erythropoetin during trial * creatinin clearance \< 50 ml/min * insufficient bone marrow function (wbc count \< 3.000/ml or platelets \< 100.000/µl) * other major symptomatic or uncontrolled illnesses not allowing to complete treatment protocol with the exception of symptoms caused by the primary disease * second malignancy, except of completely resected basal cell carcinoma of the skin
comparison of palonosetron and ramosetron for preventing patient-controlled analgesia related nausea and vomiting following spine surgery

Conditions: Postoperative Nausea and Vomiting

Summary: postoperative pain, the great concern for the patients undergoing spine surgery, has led to common use of opioid-based intravenous patient-controlled analgesia (iv-pca) postoperatively. opioid-based iv-pca offers better pain control, which could facilitate early recovery, rehabilitation and increase patient satisfaction. however, its use inevitably increases the incidence of postoperative nausea and vomiting (ponv), another great discomfort, as high as 80% in patients with multiple risk factors.therefore, there have been consistent efforts to prevent ponv with multimodal therapies such as risk stratification, modification and preventive use of antiemetics. of all antiemetics, 5-hydroxytryptamine (5-ht3) antagonist, especially ondansetron, is most commonly used and extensively studied to reduce ponv because of its efficacy and fewer side effects.\[8\] however, its efficacy is not quite satisfactory when it comes to ponv associated with opioid-based iv-pca. recently, there are many reports comparing the antiemetic efficacy between ondansetron and the 2 newly developed 5-ht3 antagonists, ramosetron and palonosetron. ramosetron is known to have a higher affinity and longer duration of binding to 5-ht3 receptor, therefore exhibits potent and sustained anti-emetic effect than previously developed 5-ht3 antagonists.palonosetron has a unique allosteric binding to the 5-ht3 receptor, which brings a higher affinity, longer duration of action and longer elimination half-time.according to the previous studies, both ramosetron and palonosetron showed superior antiemetic efficacy for ponv associated with opioid-based iv-pca to ondansetron as expected by their theoretical advantages. however, it has never been evaluated which one has superior antiemetic efficacy for opioid-based iv-pca associated ponv. therefore, in this study, we tried to evaluate the relative antiemetic efficacy of ramosetron and palonosetron in controlling opioid-based iv-pca related ponv.


Eligibility criteria:
inclusion criteria: 1. patients (20-65 years) scheduled for lumbar spinal surgery in prone position between august 2011 and july 2012. 2. all patients were using opioid-based iv-pca postoperatively for pain control exclusion criteria: 1. gastrointestinal disease 2. renal dysfunction 3. hepatic dysfunction 4. diabetes mellitus on insulin 5. pregnancy 6. use of steroid, opioid, antiemetics within 1 day before surgery 7. inability to understand verbal rating scale (vrs) 8. inability to use pca device

Keywords: palonosetron, ramosetron, ponv, opioid